Income Statements: Teva Pharmaceutical Industries Ltd (TEVA.N)
TEVA.N on New York Stock Exchange
39.34USD
24 May 2013
39.34USD
24 May 2013
Price Change (% chg)
$-0.15 (-0.38%)
$-0.15 (-0.38%)
Prev Close
$39.49
$39.49
Open
$39.50
$39.50
Day's High
$39.50
$39.50
Day's Low
$38.89
$38.89
Volume
507,809
507,809
Avg. Vol
565,646
565,646
52-wk High
$42.82
$42.82
52-wk Low
$36.64
$36.64
Interim Income Statement
|
In Millions of U.S. Dollars (except for per share items) |
2012 2012-12-31 Period Length 3 Months |
|---|---|
| Revenue | 5,249.0 |
| Other Revenue, Total | -- |
| Total Revenue | 5,249.0 |
| Cost of Revenue, Total | 2,464.0 |
| Gross Profit | 2,785.0 |
| Selling/General/Admin. Expenses, Total | 1,361.0 |
| Research & Development | 442.0 |
| Depreciation/Amortization | 13.0 |
| Interest Expense, Net - Operating | -- |
| Interest/Investment Income - Operating | -- |
| Interest Expense(Income) - Net Operating | -- |
| Unusual Expense (Income) | 639.0 |
| Other Operating Expenses, Total | -- |
| Total Operating Expense | 4,919.0 |
| Operating Income | 330.0 |
| Interest Expense, Net Non-Operating | -- |
| Interest/Invest Income - Non-Operating | -- |
| Interest Income(Exp), Net Non-Operating | (146.0) |
| Gain (Loss) on Sale of Assets | -- |
| Other, Net | -- |
| Net Income Before Taxes | 184.0 |
| Provision for Income Taxes | (110.0) |
| Net Income After Taxes | 294.0 |
| Minority Interest | 40.0 |
| Equity In Affiliates | (14.0) |
| U.S. GAAP Adjustment | -- |
| Net Income Before Extra. Items | 320.0 |
| Accounting Change | -- |
| Discontinued Operations | -- |
| Extraordinary Item | -- |
| Tax on Extraordinary Items | -- |
| Net Income | 320.0 |
| Preferred Dividends | -- |
| General Partners' Distributions | -- |
| Miscellaneous Earnings Adjustment | -- |
| Pro Forma Adjustment | -- |
| Interest Adjustment - Primary EPS | -- |
| Income Available to Com Excl ExtraOrd | 320.0 |
| Income Available to Com Incl ExtraOrd | 320.0 |
| Basic Weighted Average Shares | 867.00 |
| Basic EPS Excluding Extraordinary Items | 0.369 |
| Basic EPS Including Extraordinary Items | 0.369 |
| Dilution Adjustment | -- |
| Diluted Weighted Average Shares | 868.00 |
| Diluted EPS Excluding ExtraOrd Items | 0.369 |
| Diluted EPS Including ExtraOrd Items | 0.369 |
| DPS - Common Stock Primary Issue | 0.310 |
| Gross Dividends - Common Stock | -- |
| Total Special Items | 639.0 |
| Normalized Income Before Taxes | 823.0 |
| Effect of Special Items on Income Taxes | (194.0) |
| Inc Tax Ex Impact of Sp Items | (304.0) |
| Normalized Income After Taxes | 1,127.0 |
| Normalized Inc. Avail to Com. | 1,153.0 |
| Basic Normalized EPS | 1.330 |
| Diluted Normalized EPS | 1.328 |
UPDATE 1-Sanofi fined in Plavix generics dispute
* Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares)
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
